Cardiovascular defects in rat embryos cultured on serum from rats chronically exposed to phenytoin. 1986

M L Clapper, and M E Clark, and N W Klein, and P J Kurtz, and B D Carlton, and R S Chhabra

Headfold-stage rat embryos were cultured for 48 hours on serum from rats chronically exposed to phenytoin for periods as long as from conception until 11 months of age. Serum from phenytoin-exposed rats caused approximately 50% of the cultured rat embryos to develop cardiovascular defects as compared to 12% for controls. These morphological abnormalities included hemorrhaging of blood vessels within the embryo, pericardial edema, and absence of yolk sac circulation. Neither serum glucose nor phosphate levels nor serum osmolality were appreciably affected by phenytoin treatment. However, serum protein concentration was reduced in rats exposed to phenytoin as compared to controls. An absence of the serum protein hemopexin was associated with the reduction in serum protein levels but did not appear to be responsible for the observed cardiovascular defects.

UI MeSH Term Description Entries
D008431 Maternal-Fetal Exchange Exchange of substances between the maternal blood and the fetal blood at the PLACENTA via PLACENTAL CIRCULATION. The placental barrier excludes microbial or viral transmission. Transplacental Exposure,Exchange, Maternal-Fetal,Exposure, Transplacental,Maternal Fetal Exchange
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004477 Ectogenesis Embryonic and fetal development that takes place in an artificial environment in vitro. Ectogeneses
D004622 Embryo, Mammalian The entity of a developing mammal (MAMMALS), generally from the cleavage of a ZYGOTE to the end of embryonic differentiation of basic structures. For the human embryo, this represents the first two months of intrauterine development preceding the stages of the FETUS. Embryonic Structures, Mammalian,Mammalian Embryo,Mammalian Embryo Structures,Mammalian Embryonic Structures,Embryo Structure, Mammalian,Embryo Structures, Mammalian,Embryonic Structure, Mammalian,Embryos, Mammalian,Mammalian Embryo Structure,Mammalian Embryonic Structure,Mammalian Embryos,Structure, Mammalian Embryo,Structure, Mammalian Embryonic,Structures, Mammalian Embryo,Structures, Mammalian Embryonic
D005260 Female Females
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006330 Heart Defects, Congenital Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life. Congenital Heart Disease,Heart Abnormalities,Abnormality, Heart,Congenital Heart Defect,Congenital Heart Defects,Defects, Congenital Heart,Heart Defect, Congenital,Heart, Malformation Of,Congenital Heart Diseases,Defect, Congenital Heart,Disease, Congenital Heart,Heart Abnormality,Heart Disease, Congenital,Malformation Of Heart,Malformation Of Hearts
D006466 Hemopexin

Related Publications

M L Clapper, and M E Clark, and N W Klein, and P J Kurtz, and B D Carlton, and R S Chhabra
January 1999, Biology of the neonate,
M L Clapper, and M E Clark, and N W Klein, and P J Kurtz, and B D Carlton, and R S Chhabra
June 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,
M L Clapper, and M E Clark, and N W Klein, and P J Kurtz, and B D Carlton, and R S Chhabra
January 1984, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement,
M L Clapper, and M E Clark, and N W Klein, and P J Kurtz, and B D Carlton, and R S Chhabra
December 1986, The Journal of nutrition,
M L Clapper, and M E Clark, and N W Klein, and P J Kurtz, and B D Carlton, and R S Chhabra
January 1988, Teratology,
M L Clapper, and M E Clark, and N W Klein, and P J Kurtz, and B D Carlton, and R S Chhabra
December 2019, Medical science monitor : international medical journal of experimental and clinical research,
M L Clapper, and M E Clark, and N W Klein, and P J Kurtz, and B D Carlton, and R S Chhabra
June 1995, The Journal of nutrition,
M L Clapper, and M E Clark, and N W Klein, and P J Kurtz, and B D Carlton, and R S Chhabra
January 1980, Developments in toxicology and environmental science,
M L Clapper, and M E Clark, and N W Klein, and P J Kurtz, and B D Carlton, and R S Chhabra
August 1976, Teratology,
Copied contents to your clipboard!